femasys(US:FEMY)2025-03-27 13:20Financial Performance - Sales increased by $557,138, or 52.0%, to $1,629,108 in 2024 from $1,071,970 in 2023[7] - Net loss was $18,816,628, or ($0.85) per basic and diluted share for the year ended December 31, 2024, compared to a net loss of $14,247,124, or ($0.93) per share for 2023[7] - Total current liabilities increased to $8,582,869 in 2024 from $3,054,055 in 2023[11] - Total assets decreased to $12,445,002 in 2024 from $27,755,825 in 2023[11] Research and Development - Research and development expenses increased by $1,007,842, or 14.0%, to $8,216,543 in 2024 from $7,208,701 in 2023[7] Cash Position - Cash and cash equivalents as of December 31, 2024, was $3.5 million, with an accumulated deficit of $127.2 million[7] - The company expects current cash and equivalents to fund operations into Q3 2025[3] Revenue Expectations - U.S. revenue for FemaSeed is expected to increase by approximately 50% in Q1 2025 versus Q4 2024[3] Product Development and Partnerships - FemBloc® permanent birth control received approval in Europe, with CE mark approval pending[4] - Strategic partnerships announced for FemaSeed with CNY Fertility and HRC Fertility[4]